Coinbase Global, Inc. vs Mesoblast Limited — how do they compare? Coinbase Global, Inc. trades at $150.5 (market cap $39.20B), while Mesoblast Limited trades at $16.96 (market cap $2.21B). The key difference: Coinbase Global, Inc. is far larger — about 17.7× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| COIN | MESO | |
|---|---|---|
Market Cap | $39.20B | $2.21B |
Sector | Technology | Technology |
52-Week High | $387.27 | $20.96 |
52-Week Low | $141.09 | $12.88 |
Enterprise Value | $36.85B | $2.21B |
Signals from Pluang's Aura AI — not financial advice
COIN stock trades at $148.68, down 3.2% in the last session amid bearish technical signals and recent earnings misses. The company reported Q2 2026 revenue and EPS below expectations, marking the third consecutive quarterly loss despite achieving record 10.3% global trading volume share. Analyst sentiment remains mixed with 55% buy ratings but a Zacks strong sell designation on August 6, 2026. Technical indicators show bearish momentum with support at $141 and resistance at $152.
The outlook remains challenging with projected 2026 revenue decline to $6.3B and net loss of $988M. While the company maintains strong cash flow from operations ($2.4B in 2025) and is expanding into AI payment solutions, persistent earnings misses and crypto market volatility pose significant risks. The consensus price target of $207.20 suggests 39% upside potential if execution improves.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →